References
- Li H, Fu ZY, Arslan ME, Lee H, Cho D. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Exp Med 2021; 11: 79–92. doi: 10.5493/wjem.v11.i6.79
- Hashash JG, Francis FF, Farraye FA. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol 2021; 17: 358–66. PMID: 34602898
- Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 2020; 16: 453–61. doi: 10.1200/OP.20.00002
- Kelly-Goss MR, Badran YR, Dougan M. Update on immune checkpoint inhibitor enterocolitis. Curr Gastroenterol Rep 2022; 24: 171–81. doi: 10.1007/s11894-022-00852-7
- SERVICES USDOHAH, Health NIO, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. J Chem Soc Dalt Trans 2017. (cited 2024 Jul 15). Available at:
https://www.meddra.org/ - Ohwada S, Ishigami K, Yokoyama, Yoshihiro Kazama T, Masaki Y, Takahashi M, et al. Immune-related colitis and pancreatitis treated with infliximab. Case Reports Clin J Gastroenterol 2023; 16: 73–80. doi: 10.1007/s12328-022-01731-4
- Ofuji K, Hiramatsu K, Nosaka T, Naito T, Takahashi K, Matsuda H, et al. Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer. Clin J Gastroenterol 2021; 14: 1692–9. doi: 10.1007/s12328-021-01499-z
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714–68. doi: 10.1200/JCO.2017.77.6385
- Naito T, Nosaka T, Takahashi K, Ofuji K, Matsuda H, Ohtani M, et al. A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis. Clin J Gastroenterol 2021; 14: 1431–6. doi: 10.1007/s12328-021-01459-7
- Gallo A, Talerico R, Novello L, Giustiniani MC, D'Argento E, Bria E, et al. Collagenous colitis and atezolizumab therapy: an atypical case. Clin J Gastroenterol 2021; 14: 165–9. doi: 10.1007/s12328-020-01276-4
- Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76. doi: 10.1056/NEJMoa050516
- Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020; 8: 1–10. doi: 10.1136/jitc-2019-000451
- Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020; 123: 207–15. doi: 10.1038/s41416-020-0882-y
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625–9. doi: 10.1056/NEJM198712243172603
- Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 1–28. doi: 10.1186/s40425-017-0300-z
- Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001
- Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, et al. The characteristics of nivolumab-induced colitis: An evaluation of three cases and a literature review. BMC Gastroenterol 2018; 18: 1–5. doi: 10.1186/s12876-018-0864-1